Danburstotug Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Danburstotug Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Danburstotug can convert its Monoclonal antibody profile and PDL1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Danburstotug (query alias: Danburstotug) |
|---|---|
| Modality / target | Monoclonal antibody; PDL1; PDL1 inhibitors, ADCC, Immunomodulators |
| Highest global status | Phase 2 |
| Originator | Sorrento Therapeutics, Inc. |
| Active developers | Immuneoncia Therapeutics, Inc., Seoul National University Hospital |
The MCP disease footprint includes Cancer with a high tumour mutational burden, Locally Advanced Malignant Solid Neoplasm, Extranodal NK-T-Cell Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06365840 | Phase 2 | Recruiting | 30 | Primary endpoint not disclosed in English source |
| NCT04809012 | Phase 2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
| NCT04414163 | Phase 2 | Active, not recruiting | 23 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
1546P - Neoadjuvant anti-PD-L1 antibody therapy with IMC-001 in resectable gastric, esophageal, and hepatocellular carcinoma: A multicohort phase II trial (NeoChance study)
Phase 2; n=50; evaluation: Positive. Reported fields: MPR = 6.3 %
ENHANCED EFFICACY AND SAFETY FROM PHASE 2 STUDY OF IMC-001, ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA (R/R ENKTL), NASAL TYPE: DISTINKT STUDY
Phase 2; n=23; evaluation: Positive. Reported fields: Detailed result fields not available in English
Phase 2 study to investigate the efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study
Phase 2; n=15; evaluation: Positive. Reported fields: ORR = 60 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Danburstotug addresses Cancer with a high tumour mutational burden, Locally Advanced Malignant Solid Neoplasm, Extranodal NK-T-Cell Lymphoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 149 matched transaction record(s) under the scope “target-level comparable: PDL1.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDL1 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-08-21 | Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets | Discovery | US$150.0M stated total |
| 2026-06-26 | CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand | Approved | Financial terms not disclosed |
| 2026-02-18 | BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical combination of CXCR4, PD-1 and FAK inhibitors for treating cancer”. The milestone feed surfaced a patent-application signal described as “Methods for treating calcitonin gene-related peptide (CGRP) - expressing cancers”. The milestone feed surfaced a patent-application signal described as “Combination therapies involving claudin 18.2 antagonists for treatment of cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
